FIELD: pharmaceutics; medicine.
SUBSTANCE: inventions are the use of an antibody to PD-1 of prolgolimab in a combination with bevacizumab, paclitaxel, and a platinum preparation selected from carboplatin or cisplatin for the treatment of malignant neoplasm in a subject who needs it, where prolgolimab is administered at a dose of 1 mg/kg of the body weight or 3 mg/kg of the body weight, bevacizumab is administered at a dose of 15 mg/kg of the body weight, paclitaxel is administered at a dose of 135 mg/m2 or 175 mg/m2, carboplatin is administered at a dose of AUC 5 mg/ml/min, or cisplatin is administered at a dose of 50 mg/m2, and a method for the treatment of malignant neoplasm in a subject who needs it, including administration of therapeutically effective amount of an antibody to PD-1 of prolgolimab in a combination with bevacizumab, paclitaxel, and a platinum preparation selected from carboplatin or cisplatin.
EFFECT: efficient treatment of malignant neoplasms with a combination of prolgolimab, bevacizumab, paclitaxel, and a platinum preparation selected from carboplatin or cisplatin at specific doses of administration.
24 cl, 3 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC COMBINATIONS CONTAINING ANTI-FOLR1 IMMUNOCONJUGATES | 2016 |
|
RU2749865C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF ANTIBODY TO PD-1 OF PROLGOLIMAB AND ITS USE | 2019 |
|
RU2806320C2 |
| PD-1/PD-L1 INHIBITORS FOR TREATING CANCER | 2016 |
|
RU2714233C2 |
| COMBINED TREATMENT METHODS USING ALK INHIBITORS | 2015 |
|
RU2718914C2 |
| METHODS FOR TREATMENT OF METASTATIC CANCER TYPES, USING AXL TRAP RECEPTORS | 2018 |
|
RU2785866C2 |
| COMBINATION OF ANTI-PD-L1 ANTIBODY AND DNA-PK INHIBITOR FOR TREATING MALIGNANT NEOPLASM | 2018 |
|
RU2765997C2 |
| ANTIBODIES AGAINST PD-1 FOR TREATMENT OF LUNG CANCER | 2018 |
|
RU2771759C2 |
| ANTI-LAG-3 DOSING REGIMENS AND THEIR USE | 2018 |
|
RU2801208C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO COMPONENTS OF THE SIGNAL PATH PD-1, AND TAXANES | 2014 |
|
RU2719487C2 |
| MOLECULES OF ANTIBODIES TO PD-1 AND THEIR USE | 2016 |
|
RU2788092C2 |
